RxDoctor Payments Data

Amy Valentine

Acute Care · Jackson, MSNPI 1922546589

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.0% of the total across 227 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Medtronic at 25.2% of the total.

$4,914in general payments, 2019–2025

Across 227 payments — averaging $21.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Novartis$1K
  • Boston Scientific$611
  • Boehringer Ingelheim$610
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$199
  • Merck$168
  • plus $921 from 16 others

What the payments were for

  • Food & beverage$4,86499%
  • Education$501%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,914 in reported general payments places this provider in the 85th percentile of 223 acute care providers in Mississippi.

See all acute care providers in Mississippi

Medicare billing

Part B allowed, 2024
$47,253
Medicare patients
344
Services billed
775

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban23$13,541
EntrestoSacubitril/Valsartan19$12,129
Carvedilol111$578
Metoprolol Succinate44$473
Isosorbide Mononitrate ErIsosorbide Mononitrate41$336
Losartan Potassium44$260
Amlodipine Besylate69$239
Rosuvastatin Calcium27$228
Atorvastatin Calcium26$219
Nitroglycerin19$151
ClopidogrelClopidogrel Bisulfate15$124
Lisinopril21$118
Olmesartan Medoxomil14$97
Furosemide28$92
Hydrochlorothiazide26$85

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$34$13,54123 claims
NovartisEntresto$1,166$12,12919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 223 acute care providers in Mississippi.

Other acute care in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →